Fate Therap(FATE.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Fate Therap
FATE.US
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co.
1.820 T
FATE.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking256/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-55.50%E
    • Profit Margin-2056.79%E
    • Gross Margin-1801.69%E
  • Growth ScoreE
    • Revenue YoY-52.64%E
    • Net Profit YoY26.14%B
    • Total Assets YoY-28.53%E
    • Net Assets YoY-37.69%E
  • Cash ScoreD
    • Cash Flow Margin79.36%C
    • OCF YoY-52.64%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreB
    • Gearing Ratio36.93%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation

    Simplywall·
    US
    FATE
    +4.23%
    US
    SBIO
    +2.21%
    US
    IBB
    +1.57%
    Simplywall·
    US
    FATE
    +4.23%
    US
    SBIO
    +2.21%
    US
    IBB
    +1.57%

    Pre-market hot trades in US stocks: Fate Therap pre-market down 7.73%; MACOM Technology Solutions Holdings pre-market up 7.44%

    Price Alert·
    US
    FATE
    +4.23%
    US
    MTSI
    +4.96%
    Price Alert·
    US
    FATE
    +4.23%
    US
    MTSI
    +4.96%

    Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies

    Tip Ranks·
    US
    FATE
    +4.23%
    US
    SBIO
    +2.21%
    US
    IBBQ
    +1.95%
    Tip Ranks·
    US
    FATE
    +4.23%
    US
    SBIO
    +2.21%
    US
    IBBQ
    +1.95%

    Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks

    Tip Ranks·
    US
    FATE
    +4.23%
    US
    XBI
    +2.91%
    US
    FBT
    +1.04%
    Tip Ranks·
    US
    FATE
    +4.23%
    US
    XBI
    +2.91%
    US
    FBT
    +1.04%

    Fate Therap | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.299 M

    Earnings Watch·
    US
    FATE
    +4.23%
    Earnings Watch·
    US
    FATE
    +4.23%
    © 2026 Longbridge｜Disclaimer